These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32432431)

  • 1. [Not Available].
    Glauser M
    Rev Med Suisse; 2020 May; 16(694):1066. PubMed ID: 32432431
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular effects of androgen depletion and replacement therapy.
    Pinthus JH; Trachtenberg J; Klotz L
    Urology; 2006 Jun; 67(6):1126-32. PubMed ID: 16765164
    [No Abstract]   [Full Text] [Related]  

  • 3. [Alternative antiandrogen therapy for castration-resistant prostate cancer].
    Suzuki H; Utsumi T; Endo T; Kamijima S; Kamiya N
    Nihon Rinsho; 2016 May; 74 Suppl 3():589-94. PubMed ID: 27344799
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complications and treatment strategies of androgen deprivation therapy for prostate cancer].
    Zhou ZY; Han BM; Yang BY
    Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2641-2644. PubMed ID: 32921011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
    Carroll PR; Kantoff PW; Balk SP; Brown MA; D'amico AV; George DJ; Grossfeld GD; Johnson CS; Kelly WK; Klotz L; Lee WR; Lubeck DP; Mcleod DG; Oh WK; Pollack A; Sartor O; Smith MR; Hart C;
    Urology; 2002 Sep; 60(3 Suppl 1):1-6. PubMed ID: 12231036
    [No Abstract]   [Full Text] [Related]  

  • 7. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
    Landau D; Tsakok T; Aylwin S; Hughes S
    Clin Endocrinol (Oxf); 2012 Feb; 76(2):179-81. PubMed ID: 21951017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
    Flaig TW; Glodé LM
    Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormone replacement therapy in prostate cancer: side effects and their management].
    Bonniol R; Timsit MO
    Prog Urol; 2012 Nov; 22(14):881-5. PubMed ID: 23101960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [History and current status of endocrine therapy (hormonal therapy) for prostate cancer: General consideration].
    Namiki M; Mizokami A; Kitagawa Y
    Nihon Rinsho; 2016 May; 74 Suppl 3():557-62. PubMed ID: 27344793
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgens and depression: a review and update.
    Nead KT
    Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):175-179. PubMed ID: 30958398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal Management for Transfeminine Individuals.
    Abramowitz J; Tangpricha V
    Clin Plast Surg; 2018 Jul; 45(3):313-317. PubMed ID: 29908618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens and antiandrogens.
    Schneider HP
    Ann N Y Acad Sci; 2003 Nov; 997():292-306. PubMed ID: 14644837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients.
    Ferreira U; Leitao VA; Denardi F; Matheus WE; Stopiglia RM; Netto NR
    Prostate Cancer Prostatic Dis; 2006; 9(1):39-41. PubMed ID: 16276352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-androgen hormonal therapy for cancer and other diseases.
    Student S; Hejmo T; Poterała-Hejmo A; Leśniak A; Bułdak R
    Eur J Pharmacol; 2020 Jan; 866():172783. PubMed ID: 31712062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oestrogen and anti-androgen therapy for transgender women.
    Tangpricha V; den Heijer M
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):291-300. PubMed ID: 27916515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Clinical Presentations and Management in Complete Androgen Insensitivity Syndrome (CAIS).
    Lanciotti L; Cofini M; Leonardi A; Bertozzi M; Penta L; Esposito S
    Int J Environ Res Public Health; 2019 Apr; 16(7):. PubMed ID: 30970592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk with androgen deprivation therapy.
    Rosenberg MT
    Int J Clin Pract; 2020 Mar; 74(3):e13449. PubMed ID: 31755635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-293.
    Dong C; Chen SL; Sung WW
    Eur Urol; 2022 May; 81(5):e123. PubMed ID: 35181194
    [No Abstract]   [Full Text] [Related]  

  • 20. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
    Payne H; McMenemin R; Bahl A; Greene D; Staffurth J
    Int J Clin Pract; 2019 Sep; 73(9):1-6. PubMed ID: 30414348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.